Mar. 13 at 3:00 PM
$IBRX $XBI $IBB $QQQ $FATE IBRX Completes Scalable Manufacturing Pathway for M-ceNK Cell Therapy
Commercial Scalability: The completion of the NK2022 and NK2023 manufacturing engineering programs established a process that generates up to 5 billion cells from a single collection, yielding 8 to 10 therapeutic doses in just 12 days. This significantly lowers the potential cost of goods (COGS) compared to traditional, less efficient cell therapy manufacturing.
By validating cryopreservation from over 60 donors, the company is building a "World Bank" of ready-to-use cells. This allows for an off-the-shelf delivery model, which is essential for achieving the high-volume sales necessary to drive long-term revenue.
Readiness for Automation: The methods are now established for use in AI-driven automated robotic systems (NANT Leonardo). This readiness suggests future revenue growth will be supported by a highly efficient, automated production line rather than labor-intensive manual processes.
